Skip to main content
. 2017 Jul 21;8(33):55230–55245. doi: 10.18632/oncotarget.19420

Figure 9. Feedback loop in TKI therapy.

Figure 9

IL-6 and VEGF activate AKT-mTOR and the STAT3 signaling cascade, consequently leading to enhanced secretion of IL-6 and VEGF. Secreted IL-6 and VEGF can again re-activate tumor cells and thus trigger tumor progression. A combination therapy of TKI together with an anti-IL-6R antibody could inhibit this amplifier circle.